pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,072 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT801Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups
    In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across different IMDC…
    onclive · 2mo ago↗ source
  • The connection between periods and mental health
    Plans to oust Makary, a looming Supreme Court deadline on mifepristone, and other health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Five years after disaster, a rare disease community gets new chance at treatment
    Some boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.
    STAT · 2mo ago↗ source
← prev
page 34 of 43
next →
20
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Opinion: What addiction medicine can teach us about depending on AI
    People gradually rely on AI to reduce the discomfort of thinking. For some, that can become a problem.
    STAT · 2mo ago↗ source
  • Opinion: AI doctors should be licensed. Here’s a framework to do that
    A state-by-state approach to clinical AI won’t work. Here’s a framework that can.
    STAT · 2mo ago↗ source
  • STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
    Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.
    STAT · 2mo ago↗ source
  • Animal skin disease confirmed in clusters of European men who have sex with men
    European researchers have diagnosed a number of men who have sex with other men with a skin disease that normally infects livestock.
    STAT · 2mo ago↗ source
  • STAT+: Provider, insurer groups rush to shape No Surprises Act arbitration rules
    Doctors and insurers are battling to reshape the controversial No Surprises Act arbitration process, which has long frustrated both sides.
    STAT · 2mo ago↗ source
  • Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
    The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.
    onclive · 2mo ago↗ source
  • Five Under 5: Top Oncology Videos for the Week of 5/3
    The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
    onclive · 2mo ago↗ source
  • Experts wonder ‘Where is the CDC?’ as hantavirus outbreak unfolds
    The CDC is playing an unusually small, and quiet, role in responding to the hantavirus outbreak.
    STAT · 2mo ago↗ source
  • ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
    Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.
    onclive · 2mo ago↗ source
  • Opinion: Dr. Glaucomflecken wants the corporatization of medicine to be national news
    “We want, we need to keep medicine local. I think that's good for patients, it's good for communities,” Dr. Glaucomflecken says on the “First Opinion Podcast.”
    STAT · 2mo ago↗ source
  • Opinion: RFK Jr. allegedly ‘collected’ a dead raccoon’s penis. Was it bioethically justifiable?
    There are scientific reasons to study raccoon reproductive anatomy. But did RFK Jr.’s actions fit within a bioethical framework?
    STAT · 2mo ago↗ source
  • The OncFive: Top Oncology Articles for the Week of 5/3
    The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.
    onclive · 2mo ago↗ source
  • Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT
    R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.
    onclive · 2mo ago↗ source
  • Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
    Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.
    onclive · 2mo ago↗ source
  • Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
    Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.
    onclive · 2mo ago↗ source
  • Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
    Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.
    onclive · 2mo ago↗ source
  • Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
    Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.
    onclive · 2mo ago↗ source
  • Spain readies for evacuations as a hantavirus-hit cruise ship heads for the Canary Islands
    Spanish authorities on Friday were preparing to receive more than 140 passengers and crew members on board a hantavirus-stricken cruise ship headed for the Canary Islands.
    STAT · 2mo ago↗ source
  • STAT+: Roche to buy PathAI for $750 million
    Roche has signed a deal to acquire PathAI to speed up its use of artificial intelligence to help pathologists diagnose diseases.
    STAT · 2mo ago↗ source
  • Trump reportedly plans to fire FDA Commissioner Makary
    Makary's ouster would create another high-profile vacancy atop RFK Jr.'s health department.
    STAT · 2mo ago↗ source
  • FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
    onclive · 2mo ago↗ source
  • STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
    Capricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.
    STAT · 2mo ago↗ source